Clinical trials: Interferon Deficiency
Vitamin D Deficiency, Coronary Artery Disease
Vitamin D Repletion in Coronary Artery Disease
Vitamin D (Vit D) status is an emerging risk marker of great interest in cardiovascular disease (CVD). Lower serum levels of Vit D are associated with both cardiac risk factors and prevalent cardiovascular disease.
- Conditions
- Vitamin D Deficiency, Coronary Artery Disease, Endothelial Dysfunction, Inflammation
- Trial name
- NCT01570309
- Testing
- Ergocalciferol, Sugar pill
- Where
- 2 sites in United States
- Volunteers
- 96 people
- Sponsor
- Seth I. Sokol, M.D.
HIV Infections
Phase I/II Study of Recombinant Human Interferon-gamma (rIFN-gamma) in HIV-Infected Children
PRIMARY: To determine the safety and toxicity of recombinant interferon gamma-1b ( rIFN-gamma ) in HIV-infected children receiving ongoing zidovudine ( AZT ) or didanosine ( ddI ) therapy.
- Trial name
- NCT00000761
- Testing
- Interferon gamma-1b
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Randomized, Dose-ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects
To conduct a randomized dose-ranging study to evaluate the safety and activity of orally administered low dose interferon alfa-n3 as an immunomodulator in subjects with asymptomatic HIV-1 infection.
- Trial name
- NCT00215852
- Testing
- Alferon LDO
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- AIM ImmunoTech Inc.
Hepatitis C, Chronic, Liver Diseases
Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred2)
The purpose of this study is to validate the first round HCV early dynamics discovery within a larger population.
- Conditions
- Hepatitis C, Chronic, Liver Diseases, Interferon Deficiency
- Trial name
- sIFN-pred2 (NCT01760148)
- Testing
- interferon alpha 2b
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Junqi Niu
HIV Infections
Phase I Study of Alferon N Injection in Persons With Asymptomatic Human Immunodeficiency Virus (HIV) Infection
To determine the safety and tolerance of subcutaneous injections of natural interferon alpha (IFN) in asymptomatic HIV-positive persons and record its effects on the HIV virus in these individuals.
- Trial name
- NCT00002078
- Testing
- Interferon alfa-n3
- Where
- 2 sites in United States
- Sponsor
- Purdue Frederick
Chronic Hepatitis C Infection in HIV-Infected Persons, HIV Infections
PEG-Interferon a-2b + Ribavirin for Treatment of Chronic HRN 005 Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon
Objectives: Primary To compare the sustained virologic response (SVR) of PEGIntron plus ribavirin among patients receiving 48 weeks versus 72 weeks of therapy (defined as undetectable HCV RNA level 24 weeks after discontinuing…
- Trial name
- NCT00215891
- Testing
- PEG-Interferon a-2b + Ribavirin
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Hepatitis Resource Network
Hepacivirus, HIV Infections
Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients
Current Hepatitis C virus (HCV) treatment consists of the combination of interferon alpha 2a (IFN-alpha 2a) plus ribavirin (RBV) and it provides sustained virologic responses (SVR) on 54 to 56% on HCV monoinfected patients and…
- Trial name
- NCT02008214
- Testing
- Pentoxifylline
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Centro Universitario de Ciencias de la Salud, Mexico
Chronic Granulomatous Disease, Inflammatory Gastrointestinal Disease
Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications
Background: Chronic granulomatous disease (CGD) is a disease of the immune system, which is how the body fights germs. People with CGD get infections easily and have other health problems.
- Conditions
- Chronic Granulomatous Disease, Inflammatory Gastrointestinal Disease, Inflammatory Skin Disease, Inflammatory Lung Disease
- Trial name
- NCT05104723
- Testing
- XELJANZ (tofacitinib)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Hepatitis C, Chronic
Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C
The aim of this study is to prove the efficacy of peginterferon in HIV infected patients with liver disease caused by hepatitis C virus (HCV) when the treatment to eradicate the virus failed.
- Trial name
- NCT00122616
- Testing
- Peginterferon alpha-2a (Pegasys®), Ribavirin, HIV antiretroviral therapy
- Where
- France
- Volunteers
- 52 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Chronic Hepatitis B
Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV)
This is a single-centre prospective randomised study comparing the virological and histological response of HBV infection to lamivudine in combination with interferon versus lamivudine alone.
- Trial name
- NCT00140725
- Testing
- Lamivudine plus Polyethylene glyco-interferon alfa-2b, Lamivudine
- Where
- Hong Kong
- Volunteers
- 160 people
- Sponsor
- GlaxoSmithKline
Hepatitis C, Chronic, Hepacivirus
Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)
In this study, adult Indonesian subjects with human immunodeficiency virus (HIV) coinfected with chronic hepatitis C (CHC) will be given peginterferon alfa-2b (PEG-IFN) plus ribavirin (RBV) combination therapy.
- Conditions
- Hepatitis C, Chronic, Hepacivirus, HIV Infections
- Trial name
- NCT00687544
- Testing
- Peginterferon alfa-2b (SCH 054031), Ribavirin (SCH 018908)
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
A Study to Evaluate the Effects of Interleukin-12 (rhIL-12) in HIV-Positive Patients With CD4 Cell Counts Less Than 50 Cells/mm3 or 300-500 Cells/mm3
The purpose of this study is to determine the tolerance and effectiveness of rhIL-12 in HIV-positive patients with CD4 cell counts less than 50 cells/mm3 versus 300-500 cells/mm3.
- Trial name
- NCT00000857
- Testing
- Interleukin-12
- Where
- 16 sites in United States
- Volunteers
- 65 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis, HIV/AIDS
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV
Background: Standard treatment for the hepatitis C virus (HCV) is a combination of the drugs peg-IFN and ribavirin. However, this treatment is not very effective in people with a serious type of HCV (HCV genotype 1) and also in…
- Trial name
- NCT01443923
- Testing
- Boceprevir, Peg-Interferon-alfa 2B, Ribavirin
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immune Deficiency
Immune Benefits of Consumption of Dairy Yogurt in Elderly
To investigate the impact of consuming dairy yogurt on immun function including natural killer (NK) cell activity, circulating levels of cytokines, and immunoglobulin (Ig) in elderly.
- Trial name
- NCT03051425
- Testing
- Probiotic yogurt
- Where
- South Korea
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Yonsei University
HIV Infections
Double-Blind, Randomized, Dose Ranging Study of Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) in HIV+ Subjects
To conduct a double-blind, randomized, dose ranging study of an orally administered low dose interferon alfa-n3 (IFN-An3) immunomodulator in the treatment of symptomatic HIV+ subjects.
- Trial name
- NCT00002018
- Testing
- Interferon alfa-n3
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Interferon Sciences
HIV Infections
A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3
To evaluate the effects of three preparations of low-dose oral interferon alpha (i.e., Alferon LDO, Veldona, and Ferimmune) on HIV symptoms in HIV-infected patients.
- Trial name
- NCT00000844
- Testing
- Interferon alfa-n3, Interferon alfa-n1
- Where
- 15 sites in United States
- Volunteers
- 560 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Liver Cirrhosis, Hepatitis C Virus
Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4
Objective: To evaluate the efficacy and safety of high doses of both peginterferon-alfa 2a (360 ug per week) plus ribavirin (800 mg b.i.d.) in HIV-infected patients with compensated liver cirrhosis by HCV genotype 1 or 4 without…
- Conditions
- Liver Cirrhosis, Hepatitis C Virus, HIV Infection
- Trial name
- NCT01006031
- Testing
- Pegylated interferon alfa-2a and Ribavirin
- Where
- 4 sites in Spain
- Volunteers
- 25 people
- Sponsor
- Sociedad Andaluza de Enfermedades Infecciosas
HIV Infections
A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3
To determine the safety and efficacy of two doses of interferon alfa-2a ( IFN alfa-2a ) in combination with zidovudine ( AZT )/zalcitabine ( ddC ) versus AZT/ddC only in patients with HIV infection and CD4 count < 400 cells/mm3.
- Trial name
- NCT00000754
- Testing
- Interferon alfa-2a, Zidovudine, Zalcitabine
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HCV Coinfection, HIV Infection
Efficacy of Pegylated Interferon Plus Ribavirin Plus Nitazoxanide in HCV Genotype 4 and HIV Coinfection
Objectives: 1. Primary objective: To Evaluate the rate of sustained virological response (SVR) of pegylated interferon alfa-2b (Peg-IFN) plus ribavirin (RBV) plus nitazoxanide (NTZ) in patients coinfected by HIV and HCV genotype…
- Trial name
- NCT01529073
- Testing
- Nitazoxanide
- Where
- Spain
- Volunteers
- 45 people
- Sponsor
- Juan Macías
HIV Infections
A Study of Tumor Necrosis Factor and Human Interferon-gamma in Patients With AIDS Related Complex
To study the tolerance and toxicity of the combination of tumor necrosis factor (TNF) and interferon gamma (IFN-G) or as single agent TNF or IFN-G in HIV infected patients.
- Trial name
- NCT00001004
- Testing
- Tumor Necrosis Factor, Interferon gamma-1b
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)